Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

The U.S. Food and Drug Administration has approved BeiGene's drug to treat a type of esophageal cancer in patients who have previously received chemotherapy.

The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain patients with a type of blood cancer, the health regulator...

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

DOYU, STLA, BGNE, LEGH and WTS have been added to the Zacks Rank #1 (Strong Buy) List on December 22, 2023.

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

BeiGene said on Tuesday it has entered into an agreement with biotech company Ensem Therapeutics to acquire a global license for a cancer therapy that is ready to enter early-stage trial.

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big p...

BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.